AstraZeneca and Merck attain FDA nod for a pancreatic cancer drug
Category: #health  By Saipriya Iyer  Date: 2019-12-31
  • sharesocial_share_icon
  • Twitter
  • Facebook
  • LinkedIn

AstraZeneca and Merck attain FDA nod for a pancreatic cancer drug

The drug, dubbed Lynparza, is currently approved in almost 65 countries for the maintenance treatment of platinum-sensitive lapsed ovarian cancer.

British pharmaceutical firm AstraZeneca and Merck & Co. Inc. recently announced that its drug candidate olaparib, which is also known as Lynparza, has received approval from the U.S. Food and Drug Administration.

Reportedly, the drug is formulated to treat patients with pancreatic cancer that have mutations of genes which aids in suppressing tumors. Moreover, it is slated to double the life expectancy of pancreatic cancer patients.

As per reports, olaparib was cleared by the FDA to treat adults that have metastatic pancreatic cancer and whose health hasn’t deteriorated after 16 weeks of chemotherapy. The trial’s finding, which were published in The New England Journal of Medicine, suggested that the medicine minimized the risk of death or progression by 47%.

According to Dave Fredrickson, Executive VP of Oncology Business Unit, AstraZeneca, people previously suffering from advanced pancreatic cancer received poor outcomes because of the limited treatment advances over the past decade and aggressive nature of the disease. Lynparza comes as the only targeted drug in biomarker-selected patients going through advanced pancreatic cancer which is approved by the FDA.

Meanwhile, Roy Baynes, Chief Medical Officer & Senior Vice President, Merck Research Labs, revealed that the expanded approval of Lynparza comes as a substantial landmark for patients and reinforces the findings of germline BRCA testing in subjects with this disease.

Prior to the FDA approval, Merck & Co. Inc. and AstraZeneca had made headlines when Lynparza bagged approval from the Chinese regulators for treating a form of ovarian cancer. Sources close to the news claimed that the approval was based on Lynparza’s results from a late-stage trial in which it reduced the risk of death or disease progression by 70% when equated to placebo.
 

Source Credit: https://www.foxbusiness.com/lifestyle/astra-merck-get-fda-ok-for-pancreatic-cancer-drug



About Author

Saipriya Iyer

Email: [email protected]   linkdin twitter

Saipriya Iyer

Saipriya Iyer develops content for Market Size Forecasters, Algosonline, and myriad other platforms. A computer engineer by profession, she ventured into the field of writing for the love of playing with words. Having had a previous experience of 3 years under her bel...

More News By Saipriya Iyer

 Tabletop Tape Dispensers  market valuation to surge at healthy CAGR through 2026

Tabletop Tape Dispensers market valuation to surge at healthy CAGR through 2026

By Saipriya Iyer

A comprehensive research study on Tabletop Tape Dispensers market added by Market Study Report provides insights into the market size and growth trends of this industry over the forecast timeline. The study evaluates key aspects of Tabletop Tape D...

APAC, Europe, America region to generate massive revenues for General Well-Being Dietary Supplements market by 2026

APAC, Europe, America region to generate massive revenues for General Well-Being Dietary Supplements market by 2026

By Saipriya Iyer

MarketStudyReport.com presents latest report on global General Well-Being Dietary Supplements Market, which evaluates the growth trends of the industry through historical study and estimates future prospects based on comprehensive research. The re...

Eugenia Jambolana Extract Market to Increase Exponentially During 2027

Eugenia Jambolana Extract Market to Increase Exponentially During 2027

By Saipriya Iyer

The report Eugenia Jambolana Extract market provides high-quality information regarding the major market trends, product types and their application scope, competitive landscape, and impact of COVID-19 outbreak.

.

Request a...